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nyl-modified intermediates and actin skeleton perturbation.Simvastatin increases fibrinolytic activity in human peritoneal
These results provide a new rationale to prevent peritonealmesothelial cells independent of cholesterol lowering.
fibrin deposition and adhesion development in peritoneal dial-Background. The continuous physical and chemical irrita-
ysis patients.tion of the peritoneum in peritoneal dialysis patients can result
in a nonbacterial serositis with increased fibrin deposition, thus
promoting peritoneal fibrosis and adhesion development. By
expressing the fibrinolytic enzyme tissue-type plasminogen ac- Peritoneal dialysis (PD) is increasingly used in thetivator (t-PA) and its specific inhibitor, plasminogen activator
treatment of end-stage renal failure. The use of PD isinhibitor-1 (PAI-1), human peritoneal mesothelial cells (HMC)
accompanied, however, by many complications due toplay an important role in regulating peritoneal fibrinolysis.
Methods. Cultured HMC were used to examine the effect of the physical and chemical irritation of the peritoneum
a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, resulting in a nonbacterial inflammatory state with peri-
simvastatin, on the expression of t-PA and PAI-1. Antigen con- toneal serofibrinous exudation [1, 2]. In accordance withcentrations in the cell supernatants were measured by ELISA
this observation, we have previously demonstrated aand Northern blot analysis was conducted for mRNA expression.
plasma-independent hypercoagulatory state with perma-Results. Simvastatin time- and concentration-dependently
increased t-PA and decreased PAI-1 synthesis, reaching maxi- nent intraperitoneal fibrin formation and deposition in
mal effects after 48 hours, when simvastatin (1 mol/L) in- PD patients [3, 4]. Mesothelial and submesothelial fibrin
creased t-PA levels 5.1  0.1-fold and suppressed PAI-1 levels deposits in the peritoneal cavity can promote peritoneal2.6  0.2-fold. This was accompanied by a twofold increase in
thickening and lead to adhesion development, which ismesothelial cell-associated t-PA activity. Qualitatively similar
a cause for failure of PD [2]. Furthermore, peritonealresults were obtained in cultured human endothelial cells, but
the effects were less pronounced and required higher simva- adhesions can result in intestinal obstruction, chronic
statin concentrations. Northern blot analysis revealed that the pelvic pain and infertility in women [5, 6].
action of simvastatin on t-PA and PAI-1 expression in HMC The formation of a fibrin rich exudate is part of thecan be explained by parallel changes in t-PA and PAI-1 mRNA.
hemostatic process in response to tissue injury, the depo-The effects of simvastatin were prevented in the presence of
sition of fibrin being an essential component of normalmevalonate and geranylgeraniol, suggesting that the effect of
simvastatin on t-PA and PAI-1 synthesis is mediated through tissue repair. However, when the intraperitoneal fi-
geranylgeranyl-modified intermediates. Experiments using spe- brinolytic activity is insufficient and the deposited fibrin
cific inhibitors of geranylgeranylated Rho GTPases excluded is not removed, fibrinous adhesions can develop. Subse-a role of members of this family of small GTP-binding proteins
quently, these fibrinous deposits become organized, asin simvastatin action in HMC. The effects of simvastatin on
characterized by the ingrowth of fibroblasts and vessels,t-PA and PAI-1 expression as well as on cell shape were com-
pletely mimicked by cytochalasin D, a disrupter of cellular actin leading to peritoneal fibrosis and the development of
filaments, but not by colchicine, a disrupter of microtubules. permanent fibrous adhesions [7]. Considering this patho-
Conclusions. In conclusion, the cholesterol-lowering drug physiological background, compounds that can enhancesimvastatin is an effective stimulator of local peritoneal fibrino-
the peritoneal fibrinolytic capacity would provide a po-lytic activity, as it increases t-PA and decreases PAI-1 produc-
tential therapeutic and preventive approach to perito-tion in mesothelial cells by a mechanism involving geranylgera-
neal fibrosis and adhesion formation.
Mesothelial cells, which constitute the main cell popu-Key words: fibrin deposits, peritoneal dialysis, geranylgeranylation, ac-
lation of the innermost surface of the peritoneal wall,tin skeleton perturbation, tissue-type plasminogen activator, plasmino-
gen activator inhibitor-1, end-stage renal failure. represent a direct target for increasing this plasma-inde-
pendent fibrinolytic activity in the peritoneal cavity byReceived for publication February 19, 2002
producing both the fibrinolytic enzyme, tissue-type plas-and in revised form April 28, 2002
Accepted for publication May 9, 2002 minogen activator (t-PA), and a specific t-PA inhibitor,
plasminogen activator inhibitor type 1 (PAI-1) [8]. t-PA, 2002 by the International Society of Nephrology
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which accounts for 95% of the plasminogen activator 100 mol/L. Cytochalasin D and colchicine were ob-
tained from Sigma Chemical Co. and the specific gera-activity in the peritoneum [9], is a pivotal enzyme in
the onset of the fibrinolytic process by converting the nylgeranyltransferase-I-inhibitor (GGTI-2133) was ob-
tained from Calbiochem (Bad Soden, Germany). Theinactive zymogen plasminogen into plasmin, which de-
grades fibrin. Therefore, a therapeutic strategy to pre- Rho-kinase inhibitor ()-(R)-trans-4-(1-aminoethyl)-N-
(4-pyridyl)-cyclohexane-carboxamide (Y27632) was avent prolonged fibrin deposition could be directed at
stimulating t-PA synthesis and/or decreasing PAI-1 ex- kind gift of Yoshitomi Pharmaceutical Industries (Osaka,
Japan). C3 exoenzyme was kindly provided by Dr. M.pression.
Here we describe an interesting compound, simva- Aepfelbacher (LMU, Munich, Germany). Stock solu-
tions of the compounds were prepared in dimethyl sulf-statin, which seems an attractive candidate for stimulat-
ing the endogenous peritoneal fibrinolysis. Simvastatin oxide (DMSO; simvastatin 10 mmol/L, cytochalasin D 10
mmol/L, colchicine 10 mmol/L, GGTI-2133 10 mmol/L),belongs to a class of drugs, the statins, which inhibits the
enzyme 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) phosphate buffered saline (PBS) (MVA 1 mol/L, pH 7,
Y27632 10 mmol/L, C3 exoenzyme 3.8 g/L) or ethanolreductase and blocks the conversion of HMG-CoA to
mevalonate, the rate-limiting step in the synthesis of (GG, geraniol and farnesol 10 mmol/L) and stored at
20C. Immediately before use, the compounds werecholesterol. Statins were originally designed as choles-
terol-lowering drugs [10] and are also widely used by diluted in incubation medium to the final test concentra-
tion, whereby the concentration of DMSO did not ex-dialysis patients, who often suffer from dyslipidemia [11].
However, there is increasing evidence for beneficial ef- ceed 0.03% (vol/vol). All the compounds were used at
a concentration that was found to be effective in otherfects of statins unrelated to their lipid-lowering capacity
[12–15]. Among these favorable actions are protective cell types. Recombinant human t-PA expressed in Chi-
nese hamster ovary cells (“Activase”) was obtained fromeffects of statins against atherothrombosis. Statins in-
crease the synthesis of t-PA and decrease that of PAI-1, Genentech (San Francisco, CA, USA). Hybond-N filters,
Hyperfilm-MP and deoxycytidine 5-(-32P)triphosphateboth in cultured human endothelial cells and in rat aorta
in vivo [16–19]. We now report that simvastatin strongly (3 Ci/mol) were obtained from Amersham Pharmacia
Biotech (Buckinghamshire, UK).enhances the production of t-PA and decreases that of
PAI-1 in cultured human mesothelial cells. Furthermore,
Cell culture experimentswe investigated possible molecular mechanisms that un-
derlie the simvastatin effect on the mesothelial fibrino- Human mesothelial cells (HMC) were isolated from
the omental tissue of consenting patients undergoinglytic activity.
elective surgery as described previously [8] and the ex-
perimental protocol was approved by the local ethics
METHODS
committee. Endothelial cells from human umbilical vein
Materials (HUVEC) were isolated by use of collagenase treatment
as described by Jaffe et al [22]. Both HMC and HUVECM199 medium was obtained from Flow Laboratories
(Irvine, Scotland, UK); tissue culture plastics were from were grown in fibronectin-coated dishes in M199 supple-
mented with 20 mmol/L HEPES (pH 7.4), 2 mmol/LCostar (Cambridge, MA, USA). A crude preparation of
endothelial cell growth supplement (ECGS) was pre- glutamine, 10% (vol/vol) human serum, 10% (vol/vol)
newborn calf serum, ECGS (150 g/mL), 5 IU/mL hepa-pared from bovine brain, as described by Maciag et al
[20]. Human serum was prepared from freshly collected rin, penicillin (100 IU/mL) and streptomycin (100 g/mL)
at 37C in a 5% CO2/95% air atmosphere. The mediumblood of healthy donors, pooled and stored at 4C. New-
born calf serum was purchased from GIBCO (Grand was replaced every two to three days. Cells were subcul-
tured with mild trypsinization (1 to 2 min), using trypsin/Island, NY, USA) and was heat-inactivated (30 min at
56C) before use. Collagenase type II was from Worth- ethylenediaminetetraacetic acid (EDTA) (0.5 g/liter tryp-
sin, 0.25 g/liter EDTA), after which the cells were re-ington (Freehold, NY, USA). Monoclonal antibodies
against cytokeratin-8 and -18 and against vimentin were plated with a split ratio of 1:3. Cells from omental tissue
were pure mesothelial cells, as assessed by their uniforma gift from Dr. G. van Muijen (University of Nijmegen,
The Netherlands). Simvastatin was obtained from Merck cobblestone appearance at confluence, by the absence
of von Willebrand factor, and by the uniform positive(Boom, Amsterdam, The Netherlands), mevalonic acid
(MVA) was purchased from ICN Biomedicals (Zoeter- staining for cytokeratin-8 and -18 and for vimentin [8].
For the enzyme-linked immunosorbent assay (ELISA)meer, The Netherlands) and geranylgeraniol (GG), gera-
niol and farnesol were from Sigma Chemical Co. (St. and Northern blot experiments, confluent cultures were
used at the second or third passage, and cells were alwaysLouis, MO, USA). The specific squalene synthase inhibi-
tor TR007 was kindly provided by Dr. L.H. Cohen from refed the day before the experiment with incubation
medium, viz. M199 supplemented with 20 mmol/L HEPESour laboratory [21] and was used at a concentration of
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(pH 7.4), 10% (vol/vol) human serum, 2 mmol/L gluta- Statistics
mine and antibiotics. None of the compounds tested had Data are given as means SD. Statistical analysis was
an effect on cell viability or cell proliferation, as tested performed with the Mann-Whitney U test, and a P value
by the MTT assay (Roche Diagnostics, Almere, The of less than 0.05 was considered significant.
Netherlands) and counting the cells. This assay is based
on the cellular reduction of the tetrazolium salt MTT by
RESULTSmitochondrial dehydrogenase of viable cells to a blue
formazan product that can be measured spectrophoto- Concentration-dependency of the effect of
metrically at 545 nm. Conditioned media were obtained simvastatin on the synthesis of t-PA and PAI-1 in
by incubating cells in 2 cm2 dishes at 37C for various HMC and HUVEC
periods up to 72 hours with 0.5 mL of incubation medium Figures 1 and 2 show the effects of increasing concen-
containing the appropriate concentration of the test com- trations of simvastatin (0.1 to 3.0 mol/L) on t-PA and
pound or stock solvent. At incubation periods longer PAI-1 production in cultured HMC and HUVEC, re-
than 24 hours the medium was refreshed every 24 hours. spectively. Cells were incubated for two consecutive peri-
Conditioned media were centrifuged for five minutes at ods of 24 hours, and the results shown are production
8000 r.p.m. in a Microfuge centrifuge to remove cells and levels over the second 24-hour incubation period. In
cellular debris and samples were frozen at 20C until three separate experiments the t-PA stimulatory effect
use. The cells were used for isolation of RNA. of simvastatin in HMC became significant at 0.3 mol/L
and reached maximal values (101.4  2.0 ng/105 cellsAssays
vs. 20.1  2.4 ng/105 cells in control cells) at 1 mol/L
The assay of t-PA antigen was performed with the (Fig. 1A). As shown in Figure 1B, simvastatin concentra-
ELISA Thrombonostika t-PA (Organon-Teknika, Turn- tion-dependently lowered PAI-1 levels in HMC, re-
hout, Belgium). In this assay, free t-PA and t-PA-PAI-1 sulting in a 4.1  0.2-fold lower value at a concentration
complexes are detected with equal efficiency. PAI-1 anti-
of 3 mol/L (302.4  13.5 ng/105 cells vs. 1248  84 ng/
gen was measured by an ELISA kit (IMULYSE) ob-
105 cells in control cells). The effects of simvastatin on
tained from Biopool (Umea˚, Sweden). Plasminogen acti-
t-PA and PAI-1 synthesis in HUVEC were qualitatively
vator activity was measured in cell lysates, as HMC in
similar, but less pronounced (Fig. 2). The endothelialculture produce an excess of PAI-1 activity that impedes
increase in t-PA synthesis by simvastatin became signifi-a straightforward functional assay of t-PA activity in
cant only at a concentration of 3 mol/L (2.5  0.5 ng/conditioned media [23]. The activity assay was per-
105 cells vs. 1.4  0.1 ng/105 cells in control cells, N  3;formed as described by Verheijen et al [24], using Acti-
Fig. 2A). Corresponding PAI-1 levels dose-dependentlyvase as a standard. t-PA activity is expressed in ng/mL,
decreased to 143.9 7.7 (N 3) as compared to 477.1corresponding to the activity of equivalent amounts of
25.5 (N  3) in controls (Fig. 2B).Activase.
To evaluate whether the changes in t-PA and PAI-1
expression result in an increased fibrinolytic activity,RNA isolation and Northern blotting
t-PA activity was measured in cell lysates. A 48-hourTotal RNA was extracted from cells as described by
incubation period of cultured HMC with 1 mol/L sim-Chomczynski and Sacchi [25]. RNA samples were dis-
vastatin increased t-PA activity 2.0-fold (10.3  2.3solved in water and the RNA concentration in each
ng/mL in statin-treated cell lysate vs. 5.1  0.3 ng/mLsample was determined spectrophotometrically. Equal
in cell lysate of controls).amounts of RNA were analyzed for t-PA, PAI-1 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Time-course of the effect of simvastatin on t-PA andmRNA content by Northern blot hybridization as out-
PAI-1 expression in HMClined before [26]. In short, RNA samples were subjected
Figure 3 shows a representative time course of theto gel electrophoresis in formaldehyde-agarose gels.
effect of 1 mol/L simvastatin in HMC. As shown inAfter electrophoresis, RNA was transferred to Hybond-
Figure 3A, t-PA antigen induction became detectableN according to the manufacturer’s instructions. Hybrid-
after 12 hours, and t-PA antigen accumulation in theization was usually performed at 62C with 1 ng/mL
conditioned medium of simvastatin-treated HMC con-probe labeled by random prime labeling to approxi-
tinued to increase over the entire first 24-hour incubationmately 2 	 108 cpm/g DNA. The membranes were
period, whereas t-PA concentrations in the medium ofsubsequently exposed to Amersham Hyperfilm-MP film
control cells leveled off after 12 hours. The productionwith an intensifying screen at 80C. The intensities
of t-PA in simvastatin-treated cells was further increasedof the signals were determined using a Fujix Bas 1000
during the second 24-hour incubation period; t-PA pro-phosphoimager and expressed relative to the signal of
the GAPDH mRNA band. duction in control HMC during the second 24 hours
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Fig. 2. Concentration-dependent effect of simvastatin on t-PA andFig. 1. Concentration-dependent effect of simvastatin on tissue-type
PAI-1 release in HUVEC. HUVEC were incubated for two consecutiveplasminogen activator (t-PA) and plasminogen activator inhibitor-1
periods of 24 h with different concentrations of simvastatin and the(PAI-1) production in human mesothelial cells (HMC). HMC were
conditioned media were analyzed for t-PA (A) and PAI-1 (B) antigen.incubated for two consecutive periods of 24 hours with different concen-
Results shown are production levels over the second 24-hour incubationtrations of simvastatin and the conditioned media were analyzed for
period and are means  SD of three independent experiments per-t-PA (A) and PAI-1 (B) antigen. Results shown are production levels
formed in triplicate. *P 
 0.05 compared with control.over the second 24-hour incubation period and are means  SD of
three independent experiments performed in triplicate. *P 
 0.05 com-
pared with control.
than control levels after 48 hours (Fig. 3D). PAI-1
mRNA in simvastatin-treated HMC was decreased fromwas not significantly different from that during the first
the 12-hour time point on, resulting in 2.1-fold less24-hour period. Results obtained after a third 24-hour
mRNA expression after 48 hours (Fig. 3E).incubation period did not markedly differ from those of
Simvastatin did not alter the expression of LRP, thethe second 24-hour incubation period (data not shown),
clearance receptor of t-PA in HMC, providing furtherindicating that the t-PA-stimulating effect of simvastatin
evidence that the effect of simvastatin on t-PA productionbecame maximal after 48 hours.
is at the level of t-PA synthesis and not t-PA clearance.Simvastatin (1 mol/L) lowered the production of
PAI-1 after 8 hours, and continued to decrease PAI-1 ac-
Molecular mechanisms underlying the simvastatincumulation during the remainder of the first 24-hours and
induced changes in t-PA and PAI-1 expressionthe entire second 24-hour incubation period (Fig. 3B).
To gain insight into the molecular mechanism(s) un-To evaluate whether the observed changes in t-PA
derlying the simvastatin effect, we investigated the roleand PAI-1 production in simvastatin-treated HMC also
of several intermediates and derivatives from the choles-were reflected at the mRNA level, RNA was isolated
terol biosynthetic pathway in regulating t-PA and PAI-1from the incubated cells at the indicated times and ana-
expression. Incubation of HMC with the substrate oflyzed by Northern blotting. Figure 3C shows a represen-
3-hydroxy-3-methylglutaryl coenzyme A reductase, meva-tative time course of the effect of 1 mol/L simvastatin
lonic acid (MVA; 100 mol/L) completely reversed theon t-PA and PAI-1 mRNA in HMC. Induction of t-PA
effect of 1mol/L simvastatin on t-PA and PAI-1 synthe-mRNA became visible after 8 hours and t-PA mRNA
levels continued to increase, reaching 9.2-fold higher sis (Fig. 4). In contrast to simvastatin, an inhibitor of
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Fig. 3. Time course of t-PA and PAI-1 expression in HMC incubated
with or without simvastatin. HMC were incubated for various time
periods up to 48 hours in the presence () or absence () of 1 mol/L
simvastatin and the conditioned media were analyzed for t-PA (A) and
PAI-1 (B) antigen. The 48 hour values shown are production levels over
the second 24-hour incubation period. Results are shown as means SD
of three independent experiments performed in triplicate. *P 
 0.05
compared with control. In parallel, HMC were incubated for various
time periods with (; ) or without (; ) 1 mol/L simvastatin for
mRNA analysis. Total RNA was isolated and analyzed by Northern
blot hybridization for t-PA, PAI-1, LRP and GAPDH mRNA (C ). The
experiment shown is representative for three independent experiments.
The signals for t-PA and PAI-1 mRNA were quantified by densitometry
and adjusted for corresponding GAPDH mRNA signals. The amount of
t-PA and PAI-1 mRNA present at the different time points is expressed
relative to that found at t0. (D and E ) Results are means  SD of
three independent experiments. *P 
 0.05 compared with control.
squalene synthase (TR007; 100 mol/L), which is active sis of the isoprenoids farnesyl pyrophosphate (FPP) and
geranylgeranyl pyrophosphate (GGPP), which are in-further downstream in the cholesterol biosynthetic path-
way, did not affect t-PA and PAI-1 synthesis. These volved in the post-translational modification of specific
proteins playing a role in diverse signaling events [27–29].results indicate that end products of the cholesterol bio-
synthetic pathway are not involved in t-PA and PAI-1 Addition of geranylgeraniol (10 mol/L) to the cells,
but not farnesol (10 mol/L) or geraniol (10 mol/L),modulation. MVA is not only an intermediate in the
cholesterol biosynthesis pathway, but also in the synthe- completely quenched the modulating effect of simva-
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Fig. 4. Inhibition of the simvastatin-effect on t-PA and PAI-1 expres-
sion by mevalonic acid (MVA) and geranylgeraniol (GG) in HMC.
HMC were incubated for two consecutive periods of 24 hours with (;
) or without (; ) 1 mol/L simvastatin in the presence or absence
of 100 mol/L mevalonic acid (MVA) or 10 mol/L geranylgeraniol
(GG), and the conditioned media were analyzed for t-PA (A) and
PAI-1 (B) antigen. Results shown are production levels over the second
24-hour incubation period and are means  SD of three independent
experiments performed in triplicate. In parallel, HMC were incubated
with () or without () 1mol/L simvastatin in the presence or absence
of 100 mol/L MVA or 10 mol/L GG for mRNA analysis. Total RNA
was isolated and analyzed by Northern blot hybridization for t-PA,
PAI-1 and GAPDH mRNA (C ). The experiment shown is representa-
tive for three independent experiments. The signals for t-PA and PAI-1
mRNA were quantified by densitometry and adjusted for corresponding
GAPDH mRNA signals. The amount of t-PA and PAI-1 mRNA shown
is expressed relative to that found at control condition (D and E ).
Results are means  SD of three independent experiments. *P 
 0.05
compared with control.
statin, thus mimicking the effect of MVA (Fig. 4). The statin’s mechanism of stimulating the expression of t-PA
blocking effects of mevalonic acid and geranylgeraniol and inhibiting the expression of PAI-1 in endothelial
on simvastatin-induced changes in t-PA and PAI-1 anti- cells, smooth muscle cells and proximal tubular cells [14,
gen also were seen at the mRNA level (Fig. 4C-E). These 16, 17]. To evaluate whether the effect of simvastatin on
results indicate that simvastatin influences t-PA and t-PA and PAI-1 expression in HMC may result from the
PAI-1 synthesis through intervention in the mevalonate- inhibition of Rho proteins, we treated HMC with C3
geranylgeranyl pyrophosphate pathway. exoenzyme, a transferase that selectively adenosine di-
phosphate (ADP)-ribosylates and thus inactivates Rho
Role of geranylated Rho proteins proteins [30]. At all concentrations tested (1 to 100
g/mL) C3 exoenzyme was unable to mimic the effectThe Rho family of small guanosine 5-triphosphate
(GTP)-binding proteins are post-translationally modi- of simvastatin, both with respect to modulating t-PA and
PAI-1 synthesis as well as changing cell shape. Similarly,fied by geranylgeranylation and have been implicated in
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Fig. 5. Effects of simvastatin and cytochalasin D on mesothelial cytoskeleton. Phase-contrast microphotography (	150) of HMC which were
incubated for 48 hours in the absence or presence of simvastatin (1 mol/L), cytochalasin D (1 mol/L), simvastatin (1 mol/L) and mevalonic
acid (100 mol/L), or simvastatin (1 mol/L) and geranylgeraniol (10 mol/L).
GGTI-2133 (1 mol/L), a specific inhibitor of geranyl-
geranyltransferase I, and Y27632 (3 mol/L), a specific
Rho kinase inhibitor, were without effect on t-PA and
PAI-1 synthesis in HMC (data not shown). These results
indicate that a role of Rho in regulating t-PA and PAI-1
in HMC is unlikely, but do not exclude the involvement
of other small GTP-binding proteins.
Role of cytoskeleton organization
Since simvastatin treatment of HMC was found to
change cell shape from a cobblestone to a spherical ap-
pearance, an effect prevented by pre-treatment of the
cells with MVA or geranylgeraniol (Fig. 5), and cyto-
skeletal reorganization has been associated with altered
expression of components of the fibrinolytic system
[31–33], the question arises whether disruption of the
microfilament and/or microtubule system is a signal for
increased t-PA and decreased PAI-1 expression in HMC.
Incubation of HMC with cytochalasin D, which is known
to disrupt actin filaments, resulted in a similar change in
cell shape as seen with simvastatin (Fig. 5) and also
produced a dose-dependent increase in t-PA and a de-
crease in PAI-1 production (Fig. 6). In contrast, colchi-
cine (1 mol/L), which is known to disrupt microtubules,
had no effect on t-PA or PAI-1 synthesis (data not
Fig. 6. Effects of simvastatin and cytochalasin D on t-PA and PAI-1shown). To determine whether simvastatin and cytocha-
production in HMC. HMC were incubated for two consecutive periodslasin D exert their action by the same cellular pathway, of 24 hours with different concentrations of simvastatin (0.03 to 3.0
we have incubated HMC with simvastatin and cytocha- mol/L; ), cytochalasin D (0.03 to 3.0 mol/L; ) and combinations
of simvastatin and cytochalasin D (). Conditioned media were ana-lasin D separately and in combination at varying concen-
lyzed for t-PA (A) and PAI-1 (B) antigen. Results shown are productiontrations for 48 hours. By coincubation of the cells with levels over the second 24-hour incubation period and are means  SD
of three independent experiments performed in triplicate.simvastatin and cytochalasin D the effect on t-PA and
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PAI-1 synthesis could not be further augmented than of Rho activity could mimic the statin-effect. Although
these results do not exclude the involvement of smallwith simvastatin or cytochalasin D alone. These results
GTP-binding proteins other than Rho in regulating t-PAsuggest that the stimulatory action on t-PA and inhibi-
and PAI-1 in HMC, they point to cell-type-specific differ-tory action on PAI-1 production of simvastatin and cyto-
ences in the mechanism(s) involved in the regulation ofchalasin D occur via the same regulatory pathway.
t-PA and PAI-1 expression by statins.
In our experiments cytochalasin D, which disrupts ac-
DISCUSSION tin filaments, completely mimicked the effect of simva-
statin on t-PA and PAI-1 production, whereas colchicine,Intraperitoneal fibrin deposition is a common and seri-
which disrupts microtubuli, had no effect. Some reportsous complication of peritoneal dialysis patients leading
suggest that modulation of the cytoskeleton could regu-to peritoneal thickening and adhesion development in
late components of the fibrinolytic system [31–33], butthe peritoneal cavity [2, 34]. There is increasing evidence
the exact mechanisms are still unknown.that insufficient fibrinolysis is a critical factor in the early
An interesting question is whether dialysis patients,formation of adhesions [35]. Therapies directed at in-
who suffer from dyslipidemia and for that reason usecreasing the fibrin-dissolving capacity of the peritoneum
statins, will have beneficial effects with respect to dimin-may therefore be of relevance to reduce adhesion forma-
ished adhesion formation. Therapeutic doses of simva-tion in peritoneal dialysis patients and in patients after
statin and pravastatin have been shown to result in serumabdominal surgery. Our study describes, to our knowl-
levels of 0.02 to 0.27 mol/L and 0.09 to 0.16 mol/L,edge for the first time, that a HMG-CoA reductase inhib-
respectively [39]. These concentrations are close to thoseitor, simvastatin, is an effective drug to enhance the fi-
found to have significant effects on t-PA and PAI-1 ex-brinolytic capacity of human mesothelial cells in vitro,
pression in cultured human mesothelial cells, as reportedwhich line the whole peritoneal cavity and are an impor-
in this paper. The question arises whether the statin con-tant determinant of peritoneal fibrinolytic potential. centrations reached in the peritoneal cavity are similar
Simvastatin induced a strong increase in t-PA (mRNA to those reported in serum. Moreover, in peritoneal dial-
and protein) expression and concomitantly significantly ysis patients, fluid exchanges take place several times a
reduced PAI-1 (mRNA and protein) expression in hu- day, thus diluting and removing compounds that have
man mesothelial cells. These effects of simvastatin were diffused into the peritoneal cavity. As an anti-adhesion
time- and concentration-dependent, and also resulted in measure, it would be interesting to perform a clinical
an increased cell-associated t-PA activity. Our findings study in which statins are included in the dialysis solution
in mesothelial cells could be reproduced in human endo- to induce an increased fibrinolytic capacity of the meso-
thelial cells, albeit that the effects of simvastatin on t-PA thelium.
and PAI-1 were less pronounced and higher simvastatin In summary, we report that simvastatin strongly pro-
concentrations were needed to induce significant changes, motes the fibrinolytic capacity of human mesothelial cells
which could be attributed to the active P450-system in by a mechanism that involves geranylgeranyl-modified in-
termediates and actin skeleton perturbation. This mecha-endothelial cells [36]. A pro-fibrinolytic effect of statins
nism is different from that in other cell types as thehas now been reported for human mesothelial cells (this
family of Rho proteins was found not to be involved.paper), human endothelial cells (current study results)
The action of simvastatin on the peritoneal fibrinolytic[16–19], human vascular smooth muscle cells [16], and
system might represent a new mechanism to removefor rat proximal tubular cells [14]. In all cases the effects
early fibrin depositions in the peritoneal cavity of, amongof statins could be overcome by mevalonate and gera-
others, peritoneal dialysis patients and thereby preventnylgeraniol, but not by squalene or farnesol, indicating
peritoneal thickening and adhesion development. Sucha common regulatory mechanism involving intervention
an application of statins would add to its wide use asin the mevalonate-geranylgeranyl pyrophosphate (GGPP)
a lipid-lowering drug shown to be effective in redu-pathway. GGPP is required for the post-translational cing cardiovascular morbidity and mortality in otherwise
lipidation and membrane localization of small GTP- healthy hypercholesterolemic subjects and in patients
binding proteins that play a major role in the regulation with coronary artery disease [40, 41].
of the cell cycle and in the control of gene expression
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